Wire · opportunities
enVast Mechanical Thrombectomy Meets Primary Endpoint in Large-Thrombus STEMI Trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 August 2026 · Fusion42 review
The NATURE trial demonstrated a statistically significant 26% reduction in infarct size using Vesalio’s enVast mechanical thrombectomy device in STEMI patients with a large thrombus burden, potentially reopening debate on its place in standard treatment despite previous broad trial failures.
This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it between 29 Aug 2026 and 30 Aug 2026.
◆ ◆ The Wire takeaway
You must prepare for renewed physician interest in mechanical thrombectomy for large clot STEMI cases, as Vesalio’s trial forces guideline committees to reconsider earlier dismissals. Start tracking larger confirmatory studies as they will unlock wider adoption windows and reshape STEMI interventional standards.
◆ Coverage
2 sources · first reported 29 Aug 2026 · latest 30 Aug 2026
◆ Related on Wire
◆ Topics